OA12276A - A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. - Google Patents
A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. Download PDFInfo
- Publication number
- OA12276A OA12276A OA1200200359A OA1200200359A OA12276A OA 12276 A OA12276 A OA 12276A OA 1200200359 A OA1200200359 A OA 1200200359A OA 1200200359 A OA1200200359 A OA 1200200359A OA 12276 A OA12276 A OA 12276A
- Authority
- OA
- OAPI
- Prior art keywords
- amino
- treatment
- malarial
- compound
- chloroquine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 40
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 229960003677 chloroquine Drugs 0.000 title claims abstract description 26
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 title claims abstract description 25
- -1 (4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino Chemical group 0.000 title claims description 17
- 101100118976 Mus musculus Clint1 gene Proteins 0.000 title 1
- 239000003430 antimalarial agent Substances 0.000 claims abstract description 36
- 239000002775 capsule Substances 0.000 claims abstract description 32
- 201000004792 malaria Diseases 0.000 claims abstract description 22
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002328 chloroquine phosphate Drugs 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 33
- 229960005179 primaquine Drugs 0.000 claims description 32
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 28
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 17
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 14
- 108010061951 Methemoglobin Proteins 0.000 claims description 8
- 206010035503 Plasmodium vivax infection Diseases 0.000 claims description 8
- 230000000078 anti-malarial effect Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 7
- 230000001988 toxicity Effects 0.000 claims description 7
- 201000009976 Plasmodium vivax malaria Diseases 0.000 claims description 5
- 208000005469 Vivax Malaria Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 240000009188 Phyllostachys vivax Species 0.000 claims 3
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 abstract description 24
- 238000011269 treatment regimen Methods 0.000 abstract description 8
- ADCOUXIGWFEYJP-UHFFFAOYSA-N 3-[1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]ethylidene]oxolan-2-one Chemical compound C=12N=CC=CC2=CC(OC)=CC=1NC(C)CCCNC(C)=C1CCOC1=O ADCOUXIGWFEYJP-UHFFFAOYSA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229940086269 chloroquine phosphate 500 mg Drugs 0.000 description 3
- 229960001962 mefloquine Drugs 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 241000224028 Plasmodium cynomolgi Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- IOTAOYHKWICOBK-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1.O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 IOTAOYHKWICOBK-UHFFFAOYSA-N 0.000 description 1
- HQWQVBJUIIJTRE-LKRNKTNVSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;hydron;chloride Chemical compound Cl.CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 HQWQVBJUIIJTRE-LKRNKTNVSA-N 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000552118 Cubana Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940080435 lactose 250 mg Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229960005385 proguanil Drugs 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- ZISJLHQNEVGTIU-RFEYTNPVSA-M sodium 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoate Chemical compound [Na+].C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC([O-])=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 ZISJLHQNEVGTIU-RFEYTNPVSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 229950000856 tafenoquine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN501MU2000 | 2000-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12276A true OA12276A (en) | 2006-05-10 |
Family
ID=11097250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200359A OA12276A (en) | 2000-05-31 | 2000-08-30 | A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. |
Country Status (28)
Country | Link |
---|---|
US (1) | US7404962B1 (de) |
EP (1) | EP1292306B1 (de) |
JP (1) | JP2004505017A (de) |
KR (1) | KR20030025926A (de) |
AP (1) | AP1435A (de) |
AR (1) | AR028458A1 (de) |
AT (1) | ATE314848T1 (de) |
AU (2) | AU2001228790B2 (de) |
BR (1) | BR0005247A (de) |
CA (1) | CA2413775C (de) |
CR (1) | CR6835A (de) |
CZ (1) | CZ296875B6 (de) |
DE (2) | DE00993875T1 (de) |
DK (1) | DK1292306T3 (de) |
EC (1) | ECSP003694A (de) |
ES (1) | ES2200729T3 (de) |
GT (1) | GT200000187A (de) |
HK (1) | HK1052467B (de) |
HN (1) | HN2001000118A (de) |
HU (1) | HUP0301925A3 (de) |
MX (1) | MXPA02011883A (de) |
NO (1) | NO324774B1 (de) |
OA (1) | OA12276A (de) |
PE (1) | PE20011319A1 (de) |
PL (1) | PL200748B1 (de) |
SV (1) | SV2002000201A (de) |
WO (1) | WO2001091535A2 (de) |
ZA (1) | ZA200209726B (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2642672A1 (en) * | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
WO2010144102A1 (en) * | 2009-06-09 | 2010-12-16 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command | Pentafluorosulfanyl analogs of mefloquine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431807A (en) * | 1980-06-12 | 1984-02-14 | The United States Of America As Represented By The Secretary Of The Army | 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines |
US5219865A (en) * | 1987-05-08 | 1993-06-15 | Hoechst Aktiengesellschaft | Pharmaceutical combination for the prophylaxis and therapy of malaria |
US5373005A (en) * | 1988-04-20 | 1994-12-13 | Merrell Dow Pharmaceuticals Inc. | Despiramine in the treatment of drug-resistant malarial infections |
US5270037A (en) * | 1990-07-12 | 1993-12-14 | Boehringer Ingelheim Gmbh | Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections |
NZ246606A (en) * | 1992-02-07 | 1995-09-26 | Ciba Geigy Ag | Antimalarial compostions containing a synergistic combination of benflumetol and quinine or a derivative thereof |
-
2000
- 2000-08-30 ES ES00993875T patent/ES2200729T3/es not_active Expired - Lifetime
- 2000-08-30 CZ CZ20024071A patent/CZ296875B6/cs not_active IP Right Cessation
- 2000-08-30 AU AU2001228790A patent/AU2001228790B2/en not_active Ceased
- 2000-08-30 AU AU2879001A patent/AU2879001A/xx active Pending
- 2000-08-30 DK DK00993875T patent/DK1292306T3/da active
- 2000-08-30 PL PL372718A patent/PL200748B1/pl not_active IP Right Cessation
- 2000-08-30 HU HU0301925A patent/HUP0301925A3/hu unknown
- 2000-08-30 US US10/296,215 patent/US7404962B1/en not_active Expired - Fee Related
- 2000-08-30 WO PCT/IN2000/000081 patent/WO2001091535A2/en active IP Right Grant
- 2000-08-30 AT AT00993875T patent/ATE314848T1/de active
- 2000-08-30 AP APAP/P/2002/002672A patent/AP1435A/en active
- 2000-08-30 DE DE0001292306T patent/DE00993875T1/de active Pending
- 2000-08-30 KR KR1020027016169A patent/KR20030025926A/ko not_active Application Discontinuation
- 2000-08-30 MX MXPA02011883A patent/MXPA02011883A/es active IP Right Grant
- 2000-08-30 DE DE60025403T patent/DE60025403T2/de not_active Expired - Lifetime
- 2000-08-30 CA CA002413775A patent/CA2413775C/en not_active Expired - Fee Related
- 2000-08-30 EP EP00993875A patent/EP1292306B1/de not_active Expired - Lifetime
- 2000-08-30 JP JP2001587559A patent/JP2004505017A/ja active Pending
- 2000-08-30 OA OA1200200359A patent/OA12276A/en unknown
- 2000-10-05 EC EC2000003694A patent/ECSP003694A/es unknown
- 2000-10-13 SV SV2000000201A patent/SV2002000201A/es unknown
- 2000-10-25 GT GT200000187A patent/GT200000187A/es unknown
- 2000-11-06 BR BR0005247-7A patent/BR0005247A/pt not_active Application Discontinuation
-
2001
- 2001-05-14 AR ARP010102288A patent/AR028458A1/es unknown
- 2001-05-23 PE PE2001000469A patent/PE20011319A1/es not_active Application Discontinuation
- 2001-05-30 HN HN2001000118A patent/HN2001000118A/es unknown
-
2002
- 2002-11-28 CR CR6835A patent/CR6835A/es not_active Application Discontinuation
- 2002-11-29 ZA ZA200209726A patent/ZA200209726B/en unknown
- 2002-11-29 NO NO20025765A patent/NO324774B1/no not_active IP Right Cessation
-
2003
- 2003-07-07 HK HK03104811.6A patent/HK1052467B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060229293A1 (en) | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C | |
KR20040029360A (ko) | D-트레오메틸페니데이트로 인지 장애 및 폐경기 장애를치료하는 방법 | |
CA2664935A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
Looareesuwan et al. | Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. | |
KR20190139291A (ko) | 2-아미노-l-(2-(4-플루오로페닐)-3-(4-플루오로페닐아미노)-8,8-디메틸-5,6-디하이드로이미다조[1,2-a]피라진-7(8h)-일)에타논 및 이의 조합물의 치료 요법 | |
US6730679B1 (en) | Pharmaceutical formulations | |
Looareesuwan et al. | Treatment of acute, uncomplicated, falciparum malaria with oral dihydroartemisinin | |
OA12276A (en) | A combination kit used in the treatment of malariacontaining chloroquine and 3-(1-(((4-((6-methoxy- 8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enth{lt. | |
CA2028514C (en) | Treatment of depression | |
RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
TWI402071B (zh) | 用於治療嚴重瘧疾之雙噻唑鎓鹽或其前驅物與青蒿素或其衍生物之組合 | |
Sabchareon et al. | In vivo and in vitro responses to quinine and quinidine of Plasmodium falciparum | |
CN104546828B (zh) | 丁基苯酞或其衍生物在制备治疗或预防糖尿病并发症的药物中的应用 | |
DK166343B (da) | Forbedret piroxicamholdigt laegemiddel | |
JP2001507672A (ja) | Cis―縮合シクロペンテノ―1,2,4―トリオキサン誘導体を含有する抗マラリア組成物 | |
JP3560970B2 (ja) | ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物 | |
JP2018177773A (ja) | 医薬 | |
JP5800485B2 (ja) | 鼻汁分泌抑制用組成物 | |
US3714365A (en) | Reducing abnormally high plasma lipid levels in mammals with phenols | |
JP3064360B2 (ja) | 痴呆治療剤 | |
Alvar et al. | In vitro chloroquine-resistant falciparum malaria in Malabo, Equatorial Guinea | |
UA145542U (uk) | Спосіб лікування інфекційних захворювань | |
JP2807535B2 (ja) | 白内障治療剤 | |
Folb et al. | Drugs Used in Tropical Medicine | |
Gallant | Antidepressant overdose: symptoms and treatment |